Prostate specific antigen
The use of PSA as a screening test for prostate cancer remains controversial because no double blind, randomised controlled trial has shown that early detection reduces mortality.1,2 Despite this controversy, PSA provides valuable information for the general practitioner in everyday clinical practice, including monitoring of treated and untreated prostate cancer and prostatitis.
Brett, T. (2011). Prostate specific antigen. Australian Family Physician, 40(7), 497-500.